Activation of RIG-I in melanoma cells continues to elicit anti-tumor effects from NK cells and CD8+ T cells, even under hypoxic conditions, whereas IFN-α significantly loses its CD8+ T cell-activating ability under hypoxia. Here, RIGI is linked to melanoma.